Supplementary Table 2. Summary of treatment-emergent adverse event rates prior to and after dose escalation for patients who escalated from every other week dosing to weekly dosing during the double-blind maintenance phase

|  |  |  |
| --- | --- | --- |
|  | Prior to dose escalation N=83, 29.0PYEvents (E/100PY)  | After dose escalationN=83, 27.0PYEvents (E/100PY) |
| Any adverse event (AE) | 296 (1020.7) | 249 (922.2) |
| Serious AE | 13 (44.8) | 21 (77.8) |
| AE leading to discontinuation | 4 (13.8) | 13 (48.1) |
| Injection site reaction | 17 (58.6) | 15 (55.6) |
| Serious infection | 4 (13.8) | 4 (14.8) |
| Opportunistic infection (excluding TB) | 0 | 0 |
| Congestive heart failure | 0 | 0 |
| Demyelinating disease | 0 | 0 |
| Any malignancy | 0 | 0 |
| Hematologic event | 5 (17.2) | 4 (14.8) |
| Hepatic events | 4 (13.8) | 1 (3.7) |
| Deaths | 0 | 0 |

PY, patient-years

Three adverse events were counted prior to dose escalation and after dose escalation because of only partial information about onset date relative to the date of dose escalation.